Cargando…

A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine

The title compound, C(17)H(15)N(3)O(2), is a monoclinic polymorph (P2(1)/c with Z′ = 1) of the previously reported triclinic (P-1 with Z′ = 2) form [Gajera et al. (2013 ▸). Acta Cryst. E69, o736–o737]. The mol­ecule in the monoclinic polymorph features a central pyrazolyl ring with an N-bound p-toly...

Descripción completa

Detalles Bibliográficos
Autores principales: Jotani, Mukesh M., Gajera, Nilesh N., Patel, Mukesh C., Sung, Herman H. Y., Tiekink, Edward R. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647416/
https://www.ncbi.nlm.nih.gov/pubmed/26594387
http://dx.doi.org/10.1107/S2056989015016023
_version_ 1782401094084722688
author Jotani, Mukesh M.
Gajera, Nilesh N.
Patel, Mukesh C.
Sung, Herman H. Y.
Tiekink, Edward R. T.
author_facet Jotani, Mukesh M.
Gajera, Nilesh N.
Patel, Mukesh C.
Sung, Herman H. Y.
Tiekink, Edward R. T.
author_sort Jotani, Mukesh M.
collection PubMed
description The title compound, C(17)H(15)N(3)O(2), is a monoclinic polymorph (P2(1)/c with Z′ = 1) of the previously reported triclinic (P-1 with Z′ = 2) form [Gajera et al. (2013 ▸). Acta Cryst. E69, o736–o737]. The mol­ecule in the monoclinic polymorph features a central pyrazolyl ring with an N-bound p-tolyl group and a C-bound 1,3-benzodioxolyl fused-ring system on either side of the C atom bearing the amino group. The dihedral angles between the central ring and the N- and C-bound rings are 50.06 (5) and 27.27 (5)°, respectively. The angle between the pendent rings is 77.31 (4)°, indicating the mol­ecule has a twisted conformation. The five-membered dioxolyl ring has an envelope conformation with the methyl­ene C atom being the flap. The relative disposition of the amino and dioxolyl substituents is syn. One of the independent mol­ecules in the triclinic form has a similar syn disposition but the other has an anti arrangement of these substituents. In the crystal structure of the monoclinic form, mol­ecules assemble into supra­molecular helical chains via amino–pyrazolyl N—H⋯N hydrogen bonds. These are linked into layers via C—H⋯π inter­actions, and layers stack along the a axis with no specific inter­actions between them.
format Online
Article
Text
id pubmed-4647416
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher International Union of Crystallography
record_format MEDLINE/PubMed
spelling pubmed-46474162015-11-20 A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine Jotani, Mukesh M. Gajera, Nilesh N. Patel, Mukesh C. Sung, Herman H. Y. Tiekink, Edward R. T. Acta Crystallogr E Crystallogr Commun Research Communications The title compound, C(17)H(15)N(3)O(2), is a monoclinic polymorph (P2(1)/c with Z′ = 1) of the previously reported triclinic (P-1 with Z′ = 2) form [Gajera et al. (2013 ▸). Acta Cryst. E69, o736–o737]. The mol­ecule in the monoclinic polymorph features a central pyrazolyl ring with an N-bound p-tolyl group and a C-bound 1,3-benzodioxolyl fused-ring system on either side of the C atom bearing the amino group. The dihedral angles between the central ring and the N- and C-bound rings are 50.06 (5) and 27.27 (5)°, respectively. The angle between the pendent rings is 77.31 (4)°, indicating the mol­ecule has a twisted conformation. The five-membered dioxolyl ring has an envelope conformation with the methyl­ene C atom being the flap. The relative disposition of the amino and dioxolyl substituents is syn. One of the independent mol­ecules in the triclinic form has a similar syn disposition but the other has an anti arrangement of these substituents. In the crystal structure of the monoclinic form, mol­ecules assemble into supra­molecular helical chains via amino–pyrazolyl N—H⋯N hydrogen bonds. These are linked into layers via C—H⋯π inter­actions, and layers stack along the a axis with no specific inter­actions between them. International Union of Crystallography 2015-09-12 /pmc/articles/PMC4647416/ /pubmed/26594387 http://dx.doi.org/10.1107/S2056989015016023 Text en © Jotani et al. 2015 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
spellingShingle Research Communications
Jotani, Mukesh M.
Gajera, Nilesh N.
Patel, Mukesh C.
Sung, Herman H. Y.
Tiekink, Edward R. T.
A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine
title A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine
title_full A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine
title_fullStr A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine
title_full_unstemmed A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine
title_short A monoclinic polymorph of 4-(2H-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1H-pyrazol-5-amine
title_sort monoclinic polymorph of 4-(2h-1,3-benzodioxol-5-yl)-1-(4-methyl­phen­yl)-1h-pyrazol-5-amine
topic Research Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647416/
https://www.ncbi.nlm.nih.gov/pubmed/26594387
http://dx.doi.org/10.1107/S2056989015016023
work_keys_str_mv AT jotanimukeshm amonoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT gajeranileshn amonoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT patelmukeshc amonoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT sunghermanhy amonoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT tiekinkedwardrt amonoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT jotanimukeshm monoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT gajeranileshn monoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT patelmukeshc monoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT sunghermanhy monoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine
AT tiekinkedwardrt monoclinicpolymorphof42h13benzodioxol5yl14methylphenyl1hpyrazol5amine